- Home
- PFN vs TRVI Comparison
PFN vs TRVI Comparison
Compare PFN & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFN
- TRVI
- Stock Information
- Founded
- PFN 2004
- TRVI 2011
- Country
- PFN United States
- TRVI United States
- Employees
- PFN N/A
- TRVI N/A
- Industry
- PFN Finance/Investors Services
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- PFN Finance
- TRVI Health Care
- Exchange
- PFN Nasdaq
- TRVI Nasdaq
- Market Cap
- PFN 692.7M
- TRVI 725.7M
- IPO Year
- PFN N/A
- TRVI 2019
- Fundamental
- Price
- PFN $7.50
- TRVI $7.87
- Analyst Decision
- PFN
- TRVI Strong Buy
- Analyst Count
- PFN 0
- TRVI 9
- Target Price
- PFN N/A
- TRVI $19.94
- AVG Volume (30 Days)
- PFN 331.7K
- TRVI 1.9M
- Earning Date
- PFN 01-01-0001
- TRVI 08-07-2025
- Dividend Yield
- PFN 11.66%
- TRVI N/A
- EPS Growth
- PFN N/A
- TRVI N/A
- EPS
- PFN N/A
- TRVI N/A
- Revenue
- PFN N/A
- TRVI N/A
- Revenue This Year
- PFN N/A
- TRVI N/A
- Revenue Next Year
- PFN N/A
- TRVI N/A
- P/E Ratio
- PFN N/A
- TRVI N/A
- Revenue Growth
- PFN N/A
- TRVI N/A
- 52 Week Low
- PFN $5.94
- TRVI $2.36
- 52 Week High
- PFN $7.58
- TRVI $8.11
- Technical
- Relative Strength Index (RSI)
- PFN 62.84
- TRVI 74.32
- Support Level
- PFN $7.34
- TRVI $6.67
- Resistance Level
- PFN $7.51
- TRVI $8.11
- Average True Range (ATR)
- PFN 0.04
- TRVI 0.41
- MACD
- PFN 0.00
- TRVI 0.17
- Stochastic Oscillator
- PFN 77.50
- TRVI 89.66
About PFN PIMCO Income Strategy Fund II
PIMCO Income Strategy Fund II is a closed-ended fixed income mutual fund. The company's primary investment objective is to seek high current income, consistent with the preservation of capital. The fund invests in a range of securities, such as corporate bonds and notes, non-agency mortgage-backed securities, asset-backed securities, municipal bonds and notes, short-term instruments, sovereign Issues, preferred Securities and others.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.